Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented chronic hepatitis C (CHC) genotype 1 infection~* Treatment naïve or failed previous interferon/ribavirin therapy (≥12 uninterrupted weeks)~* Weigh between 10 kg to 90 kg inclusive at screening and baseline (Day -1).~* Body Mass Index (BMI) from the 5th to the 95th percentile for the participant's age and gender, inclusive, per tables from the Center for Disease Control and Prevention, USA~* Use of acceptable methods of contraception for at least 3 months prior to baseline and continue on study~Exclusion Criteria:~* Co-infection with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive).~* Treatment with ribavirin within 90 days, or any interferon-alfa within 30 days~* Discontinued from interferon treatment due to adverse events~* Currently receiving antiviral/immunomodulating therapy for hepatitis C~* Prior treatment with an HCV protease inhibitor~* Prior treatment with any known hepatotoxic agent (including herbal remedies)~* Use of investigational drugs within 30 days of enrollment into study~* Evidence of de-compensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy.~* Substance abuse (including but not limited to alcohol abuse, illicit drugs,~inhalational drugs, marijuana use, etc) any time prior to entry into the study~* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug.~* Pregnant or breastfeeding female~* Meeting any of the laboratory exclusion criteria

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Children 17 to ≥13 years (Type: EXPERIMENTAL): Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such pudding or applesauce. The first 4 participants were treated with a 11.4 mg/kg dose of boceprevir powder. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
- Cohort 2: Children <13 to ≥7 years (Type: EXPERIMENTAL): Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 1. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
- Cohort 3: Children <7 to ≥3 years (Type: EXPERIMENTAL): Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 2. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility